Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey.
Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey.
Int J Surg. 2016 Aug;32:71-7. doi: 10.1016/j.ijsu.2016.06.041. Epub 2016 Jun 27.
The purpose of this study was to investigate the clinicopathological characteristics, treatment methods, and prognostic factors in women with uterine papillary serous carcinoma (UPSC) and uterine clear-cell carcinoma (UCCC).
All patients who had undergone surgery for UPCS and UCCC between January 1995 and December 2012 were retrospectively reviewed. Patients with missing data, who did not undergo surgical staging and patients with mixed tumor histology were excluded. Multivariate regression models were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).
A total of 49 UPSC and 22 UCCC women were included. The majority of the patients were at stage I [IA, 22 (31%) and IB, 18 (25.4%)]. Stages II, III, and IV were identified in 9 (12.7%), 13 (18.3%), and 9 (12.7%) of cases, respectively. Optimal cytoreduction was achieved in 71.8% of cases. Recurrences occurred in 16 patients (22.5%). The 5-year OS rates were 67% for UPSC; 76% for UCCC; 68% for both histology, respectively. Multivariate analysis pointed out that age>67 years (odds ratio (OR): 3.85, p = 0.009 and OR: 3.35, p = 0.014), >50% myometrial invasion (MI) (OR: 2.87, p = 0.037 and OR: 2.46, p = 0.046) and optimal cytoreduction (OR: 3.26, p = 0.006 and OR: 2.77, p = 0.015) were the independent prognostic factors for both PFS and OS.
Our study demonstrated that optimal cytoreduction, >50% MI, and age >67 years are the most significant factors affecting survival in women with UPSC and UCCC.
本研究旨在探讨女性子宫乳头状浆液性癌(UPSC)和子宫透明细胞癌(UCCC)的临床病理特征、治疗方法和预后因素。
回顾性分析 1995 年 1 月至 2012 年 12 月期间接受 UPSC 和 UCCC 手术治疗的所有患者。排除数据缺失、未行手术分期和混合肿瘤组织学的患者。采用多变量回归模型确定总生存(OS)和无进展生存(PFS)的危险因素。
共纳入 49 例 UPSC 和 22 例 UCCC 患者。大多数患者处于 I 期[IA 期 22 例(31%)和 IB 期 18 例(25.4%)]。II 期、III 期和 IV 期分别为 9 例(12.7%)、13 例(18.3%)和 9 例(12.7%)。71.8%的患者达到了最佳减瘤效果。16 例患者出现复发。UPSC 的 5 年 OS 率为 67%,UCCC 为 76%,两种组织学均为 68%。多因素分析表明,年龄>67 岁(优势比(OR):3.85,p=0.009 和 OR:3.35,p=0.014)、>50%肌层浸润(MI)(OR:2.87,p=0.037 和 OR:2.46,p=0.046)和最佳减瘤效果(OR:3.26,p=0.006 和 OR:2.77,p=0.015)是影响 PFS 和 OS 的独立预后因素。
本研究表明,在 UPSC 和 UCCC 女性中,最佳减瘤效果、>50%MI 和年龄>67 岁是影响生存的最重要因素。